Sr. Director/Exec. Director of Cheminformatics for Early Molecule Discovery at Eli Lilly and Company

Indianapolis, Indiana, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, HealthcareIndustries

Requirements

Demonstrated ability of successfully applying in silico technologies to drive the discovery of quality lead-like molecules
Experience with cheminformatics, ML/AI, and advanced analytical approaches
Strong scientific leadership and strategic guidance on cheminformatics and applied ML/AI
Excellent people skills and a positive, can-do attitude
Ability to thrive in a highly interactive and fast-paced team environment
Hands-on experience applying cheminformatics and AI/ML technologies

Responsibilities

“Lead from the bench” by judiciously building up and applying state-of-the-art cheminformatics, ML/AI, and advanced analyses capabilities to enable library design, hit identification, prioritization, and hit-to-lead progression across multiple target classes and modalities
Provide scientific leadership and strategic guidance on cheminformatics and applied ML/AI approaches to drive data-driven drug discovery
Encourage close collaborations and initiatives with computational colleagues, medicinal chemists, and other cross-functional partners to generate well-poised molecules

Skills

Key technologies and capabilities for this role

CheminformaticsMachine LearningArtificial IntelligenceIn Silico TechnologiesLibrary DesignHit IdentificationVirtual ScreeningData-Driven ModelingAdvanced Analytics

Questions & Answers

Common questions about this position

What is the salary for this Sr. Director/Exec. Director of Cheminformatics role?

This information is not specified in the job description.

Is this position remote or does it require working from an office?

This information is not specified in the job description.

What key skills are required for this cheminformatics leadership role?

The role requires demonstrated expertise in applying in silico technologies to drive lead-like molecule discovery, experience with cheminformatics, ML/AI, and advanced analytical approaches, strong scientific leadership, and hands-on experience applying these technologies.

What is the company culture like at Eli Lilly for this team?

The company emphasizes a culture of innovation, utilizing cutting-edge science, and operates in a highly interactive and fast-paced team environment that fosters close collaborations across cross-functional teams.

What makes a strong candidate for this Early Molecule Discovery leadership position?

A strong candidate will have demonstrated success applying in silico technologies to molecule discovery, hands-on expertise in cheminformatics and AI/ML, strong leadership skills, excellent people skills, and the ability to thrive in a fast-paced, collaborative environment.

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free